Skip to main content
OpenTrials
Completed

NCT Number: NCT02887495

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Scleroderma Connective Tissue Diseases Scleroderma, Diffuse Scleroderma, Systemic Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Victoria K Shanmugam

Washington D.C., District of Columbia, 20037, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years
  • Able to give informed consent.
  • Diagnosed with scleroderma or with positive autoantibodies

Exclusion criteria

  • < 18 years old

Treatment and study plan

Primary outcomes

  1. Modified Rodnan Skin Score

    Time frame: 10 years

Secondary outcomes

  1. Medsger Severity Score

    Time frame: 10 years

Sponsors and collaborators

Lead sponsor

George Washington University

Other

Registry information

Important dates

Study start
2014
Primary completion
2022
Study completion
2022
First posted
Sep 2, 2016
Registry last updated
Jul 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.